I'd guess that Mellor has had chats with SNDK side of the equation, its his job to deal with the big names, seems like that was a message from SNDK to the public.
Zacks will sometimes have an analyst provide detailed coverage and other times, they go with their plug-in calculator algos.
Because they increased outstanding shares to 17.7M when they raised cash. 17.7 x PPS (2.85). Trading platforms finally updated the share count to calculate market cap.
Did anyone else get a survey, from Shiv Kapoor via (SurveyMonkey) about their recent round robin presentation Analyst Day? I wrote in Renazorb as a candidate that I was "excited about", I think they should look to partner that outside the US, it seems like a decent enough drug to be approved with a good sized market.
The "Market cap minus cash now" = $37.445M, exercise 3M warrants at $4.15 to increase to 20.7M shares O/S = $62M market cap minus cash. They have ~ 0.68 cash per share.
Assuming 3M warrants at $4.15 to get $12M cash:
Market cap minus cash now ($37.445M) + $24M cash = $61,445M and adding 3M shares = 20.7 O/S = $2.96PPS if you maintain the same "market cap minus cash now".
You increase shares but you add cash, 24M cash is $1.16/share with 20.7M shares and if you are profitable, that cash won't decrease. It allows you to make more money.
You aren't diluting for no reason, you are diluting to get cash on the balance sheet, that strengthens the company. No one is going to force the warrant holders to exercise their warrants at $4.15, they will only do it if they think they will get a return on their shares from $4.15, which is good for shareholders. Dilution is not the boogey man.
Growth isn't really trouble, $16.8M was above the highest estimate for revenue, and they guided 50% growth in revenue for 2015. $15.2M revenue was their previous high for a quarter, Sept. 2012 3rd Q
Patent infringement case is also in the works, to go along with trade secret, patents already validated as they were prevented from being re-examined.
"Diablo will not have an legal case to make. Their only hope would be to use misdirection and try to characterize NLST as bad actors; we believe that the opposite has happened"
Gross margins at 61-63% are very good. I love the deal with Aspire for at the market capital raises, they can be selective when they decide to raise and they can just nibble a few here and there, much better than a lump sum capital raise, much easier on the price action.
I don't think they will need to raise much money at all to reach cash flow positive, but they needed a little infusion of capital, this allows it without getting in the way of momentum. They intend to partner with hMatrix later on, Dan has done a great job and if he can secure NYSE listing, then kudos to him.
Do they have to present their case for damages, the amount?
People don't understand just how important an advancement AeroSurf would be, the promise it holds. Just reading about how AeroSurf babies would regain their pink color more readily and how they need less oxygen and there is less CO2 is a big positive. Surfaxin can take a back seat if it means having the capital to push AeroSurf.
I do think someone would partner with DSCO for Surfaxin.
Yup criskush, this is just another perfect example of bashers not having any clue about what they are saying, this has nothing to do with any claims. Three PATENTS (all claims) are given the all clear by USPTO, they are denied re-exams.
Both parties are now barred from filing IPR petitions on the '185, '833, and '187 patents in the pending litigation. Every claim in those patents is secure from USPTO re-exams.
NCE, NME and Orphan are as equally important to know, NCE precludes generic from filing ANDAs for 5 years while NME they can file immediately. Orphan gives 7 years protection from generic filings.
Did you happen to catch the web address I posted? The Roth conference presentation is still up, search roth conference webcast, get to the Roth website.